Harnessing the power of antibodies

Therapeutic portfolio

Pure Biologics achieves key milestone with successful completion of Phase 0 study for PBA-0405 in cancer treatment

Pure Biologics with partnership agreement for PB004 and PB003G projects

PB004 project – first administration in a Phase 0 clinical trial

PB003G project – the FDA approval to proceed with Phase 0 clinical trial

PB004 project – the FDA approval to proceed with Phase 0 clinical trial

Therapeutic portfolio

Pure Biologics’ therapeutic portfolio includes new immunooncology therapies. In these innovative projects we use antibody technologies to develop molecules with therapeutic potential.

Investors & media

Pure Biologics is the first entity in Poland to focus on development of completely new, not generic or biosimilar, biological drugs based on antibodies. This is a challenge that is currently a leading trend in the global pharmaceutical industry.